AbCellera reports FY22 EPS 50c, consensus 64c

Reports FY22 revenue $485.4M, consensus $517.6M. "In 2022 we demonstrated strong topline results and ongoing success in our partnering business. Even more significant is the progress we made in scaling and expanding the capabilities of our engine during the year," said Carl Hansen, CEO. "We believe we are at an inflection point and expect to drive deeper value with partners and to prove our ability to consistently deliver clinical candidates for patients in need."